title: Zoledronate-pulsed dendritic cell-based anticancer vaccines.
abstract: The addition of zoledronate to tumor-associated antigen (TAA)-loaded dendritic cells (DCs) promotes the activation of interferon γ-secreting Vγ9 γδ T cells, in turn eliciting TAA-specific CD8+T-cell responses. Immunological responses induced by zoledronate-pulsed DC-based vaccines have been associated with therapeutic effects in clinical trials.
authors: Seta Clinic; Tokyo, Japan.
authors: Takashi
authors: T
authors: Kamigaki
authors: Masashi
authors: M
authors: Takahara
authors: Ryuji
authors: R
authors: Maekawa
authors: Shigenori
authors: S
authors: Goto
keywords: Wilms’ tumor 1; dendritic cell; electroporation; intratumoral injection; tumor-associated antigen-derived peptide; zoledronate